Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSETTA Gastric-204 pumitamig versus nivolumab plus chemotherapy in first-line advanced gastroesophageal adenocarcinoma
2025-523263-37-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) comparing Pumitamig plus chemotherapy with Nivolumab plus chemotherapy (2 arms). Primary endpoints: Objective response rate, Progression-free survival and 1 more. Planned start Apr 2026; status: authorised.
02
Drugs
pumitamignivolumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2025-523263-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523263-37-00.